Sci Rep:利用数学模拟的前列腺癌个性化抑制研究

2018-02-25 AlexYang MedSci原创

最近,有研究人员利用150名病人通过一个固定的治疗计划进行的间歇性雄激素抑制(IAS)治疗的数据,为每一位病人回顾性的设计了一个个性化的治疗计划。考虑到了前列腺特异性抗原(PSA)的不确定性,研究人员通过对每位病人的时间点采取随机重复取样的方法为每一位病人评估了100套参数值。之后,研究人员鉴定了3种类型并且根据以下3种类型鉴定分类:类型1:复发,即PSA的散度,可以通过IAS来抑制;类型2:复发

最近,有研究人员利用150名病人通过一个固定的治疗计划进行的间歇性雄激素抑制(IAS)治疗的数据,为每一位病人回顾性的设计了一个个性化的治疗计划。

考虑到了前列腺特异性抗原(PSA)的不确定性,研究人员通过对每位病人的时间点采取随机重复取样的方法为每一位病人评估了100套参数值。之后,研究人员鉴定了3种类型并且根据以下3种类型鉴定分类:类型1:复发,即PSA的散度,可以通过IAS来抑制;类型2:复发可以通过IAS来进行比任何持续性的雄激素抑制(CAS)更长的推迟;类型3:IAS无效,因此CAS在长期用药时更为合适。更多的是,研究人员通过搜索所有的可能治疗计划,在100个参数集中最差的案例中,通过最小化3年后的PSA,获得了一个激素治疗的治疗计划。如果在100个集中最为常见的是类型1,则最大PSA倾向于在IAS中保持少于100ng/ml的状态要比CAS时间更长,然而在其他案例中没有统计学显著差异。因此,人们应当对数学个性化IAS应当进行前瞻性的研究。

原始出处:

Yoshito Hirata, Kai Morino, Koichiro Akakura et al. Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling. Sci Rep. 08 Feb 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=291390, encodeId=6da72913907e, content=学习了.思路比较新颖.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Tue Feb 27 11:23:12 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291341, encodeId=09f129134165, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Tue Feb 27 08:59:21 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291334, encodeId=0ede291334cf, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Feb 27 08:51:42 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291327, encodeId=985f29132e27, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Feb 27 08:25:12 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-02-27 梦想起航ing

    学习了.思路比较新颖.谢谢分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=291390, encodeId=6da72913907e, content=学习了.思路比较新颖.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Tue Feb 27 11:23:12 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291341, encodeId=09f129134165, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Tue Feb 27 08:59:21 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291334, encodeId=0ede291334cf, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Feb 27 08:51:42 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291327, encodeId=985f29132e27, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Feb 27 08:25:12 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-02-27 飛歌

    学习了很有用不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=291390, encodeId=6da72913907e, content=学习了.思路比较新颖.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Tue Feb 27 11:23:12 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291341, encodeId=09f129134165, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Tue Feb 27 08:59:21 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291334, encodeId=0ede291334cf, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Feb 27 08:51:42 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291327, encodeId=985f29132e27, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Feb 27 08:25:12 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-02-27 明月清辉

    谢谢分享.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=291390, encodeId=6da72913907e, content=学习了.思路比较新颖.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Tue Feb 27 11:23:12 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291341, encodeId=09f129134165, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Tue Feb 27 08:59:21 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291334, encodeId=0ede291334cf, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Feb 27 08:51:42 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291327, encodeId=985f29132e27, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Feb 27 08:25:12 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-02-27 龙胆草

    学习谢谢分享

    0

相关资讯

CLIN CANCER RES:恩杂鲁胺对卡巴他赛药代动力学的影响

在转移性去势抵抗前列腺癌的临床研究中,目前正在探索紫杉烷类联合AR靶向药物,即恩杂鲁胺和阿比特龙的治疗效果是否可以得到增强。因为恩杂鲁胺可以诱导CYP3A4酶而紫杉烷类药物由这种酶代谢,需要研究其潜在的药物之间的相互作用。CLIN CANCER RES近期发表了一篇文章研究这一问题。

Oncol Rep: PARP1-siRNA能够抑制人类前列腺癌细胞的生长和恶化

Poly聚合酶(PARP)抑制剂,比如奥拉帕尼或者rucaparib,在BRCA1/2缺陷型肿瘤中展现出了治疗活性。然而,虽然PARP抑制剂(PARPi)主要调控PARP的激活而不是表达,是否PARP特异性针对的小干扰RNA(siRNA)与PARRPi具有与相同的功能仍旧未知。最近,有研究人员阐释了不考虑BRCA1/2的变异,PARP-1能够减少前列腺癌(PCa)细胞的恶化。PARP1的沉默能够显

FDA批准强生前列腺癌新疗法 可延长生存期超2年

近日,美国食品药品监督管理局(FDA)宣布,批准强生(Johnson & Johnson)旗下的杨森(Janssen)公司下一代雄激素受体抑制剂Erleada(apalutamide),用于治疗非转移性去势抵抗性前列腺癌(NM-CRPC)患者。这些患者虽然在接受激素治疗,但肿瘤仍继续增长。值得一提的是,它是首个经FDA批准的用于非转移性去势抵抗性前列腺癌的疗法。美国国立卫生研究院的国家癌

CLIN CANCER RES:阻断神经内分泌分化和巨噬细胞反馈回路可以改善恩杂鲁胺对前列腺癌治疗效果

去势治疗(ADT)会导致前列腺癌产生耐药。ADT耐药与神经内分泌分化和肿瘤相关巨噬细胞有关。CLIN CANCER RES近期发表了一篇文章,研究恩杂鲁胺诱导的神经内分泌分化和肿瘤相关巨噬细胞及其机制。

Sci Rep:在前列腺癌细胞中,白花丹素诱导的差异基因表达受雄激素受体调控

小鼠获得性前列腺PTEN-P2肿瘤或者体内前列腺组织的 5-hydroxy-2-methyl-1,4-naphth oquinone(白花丹素)处理能够在去势小鼠中导致肿瘤退化,但是在完整的小鼠中没有上述情况。这表明了由于白花丹素处理,双氢睾酮(DHT)在这些睾丸中的产生也许阻止了细胞的死亡,但是潜在的机制仍旧不清楚。最近,有研究人员在白花丹素和DHT组合处理的细胞中进行了RNA-seq测序分析,

Urol J:患有前列腺癌且经历雄激素阻断治疗的病人中抑郁与许多风险因素之间的相关性分析

最近,有研究人员在经历雄激素阻断疗法(ADT)治疗前列腺癌的患者中鉴定了影响抑郁的因素。研究包括了那些拜访精神病门诊的患有前列腺癌的患者,并且他们都经历了ADT且伴随着抑郁症状。为了评估抑郁症状,研究人员使用了白氏抑郁症量表(BDI)。为了鉴定影响抑郁症的风险因素,研究人员进行了单变量和多变量的线性回归分析。研究发现,参与者(n=45)的平均年龄、ADT起始治疗年龄和ADT持续时间、血清睾丸素水平